XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Early LGS-CORE Registry Data Show Only 4% of Reported Treatments Stopped All Seizures in Lennox-Gastaut Syndrome

October 20, 2026

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ — The Lennox-Gastaut Syndrome (LGS) Foundation will present the first data from its LGS Collaborative Outcomes Registry (LGS-CORE) at the 2026 NORD Rare Diseases & Orphan Products Breakthrough Summit, October 25 to 27 in Washington, DC. LGS-CORE is a…

Source: Read More

Announcements

2026 NORD Rare Diseases & Orphan Products Breakthrough Summit, Lennox-Gastaut Syndrome, LGS Collaborative Outcomes Registry, LGS-CORE, pr-newswire

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

30 DAY

60 DAY

90 DAY

120 DAY

UNLIMITED

Get FREE Biotech Stock Catalyst Reports

Email